Zibotentan
SIGMA/SML1550 - ≥98% (HPLC)
Synonym: N-
CAS Number: 186497-07-4
Empirical Formula (Hill Notation): C19H16N6O4S
Molecular Weight: 424.43
MDL Number: MFCD09955343
Linear Formula: C19H16N6O4S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C19H16N6O4S/c1-12-10-2 |
| InChI key | FJHHZXWJVIEFGJ-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | O=S(C1=C(C2=CC=C(C3=NN=CO |
| solubility | DMSO: 5 mg/mL, clear (warmed) |
| storage temp. | −20°C |
| Biochem/physiol Actions: | Zibotentan has been found to inhibit cell proliferation, invasion and metastasis in cancer models. In clinical trials on patients with castration-resistant prostate cancer and bone metastasis, who were pain-free or had mild pain, zibotentan treatment resulted in better overall survival as compared to placebo. |
| Biochem/physiol Actions: | Zibotentan is a potent and selective endothelin ET(A) receptor antagonist with an IC50 of 21 nM for the ETA receptor subtype and no binding observed even at 10,000 nM for ETB. |
| Biochem/physiol Actions: | Zibotentan is a potent and selective endothelin ET(A) receptor antagonist. |
| General description: | Zibotentan is an orally bioavailable, non-peptide ETA (endothelin) receptor-specific antagonist, with no activity against ETB receptor. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |


